Drug tissue concentration and STAT3 modulation as determinants of tofacitinib response in ulcerative colitis

Bram Verstockt(Universitair Ziekenhuis Leuven), Séverine Vermeire(KU Leuven), Pejman Rahimian(Mirati Therapeutics (United States)), Marc Ferrante(Universitair Ziekenhuis Leuven), Dahham Alsoud(KU Leuven), Jeff Smith(Mirati Therapeutics (United States)), Geert D’Haens(Amsterdam University Medical Centers), Joep van Oostrom(Amsterdam Neuroscience), Sujay Singh(Mirati Therapeutics (United States)), João Sabino(KU Leuven), Sharat Singh(Mirati Therapeutics (United States)), Sare Verstockt(KU Leuven), Jack Stylli(Georgetown University), Ariella Kelman(Mirati Therapeutics (United States)), Sara van Gennep(Amsterdam Neuroscience)
Journal of Crohn s and Colitis
April 17, 2025
10.1093/ecco-jcc/jjaf063
Cited by 5

Related Papers

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis
|Gut|2013|1.9k
ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
|Journal of Crohn s and Colitis|2018|1.8k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k